NCT06047197View on ClinicalTrials.gov

Phase I Clinical Trial of RC19D2 Cell Injection in the Treatment of Diffuse Large B-cell Lymphoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

September 5, 2023

Primary Completion Date

September 5, 2026

Study Completion Date

December 5, 2026

Conditions
Recurrent Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-cell Lymphoma
Interventions
BIOLOGICAL

RC19D2 cell injection

The functional component of RC19D2 cell injection is T cells that have been genetically modified to express anti CD19 chimeric antigen receptors.

Trial Locations (1)

Unknown

RECRUITING

Hematology Hospital of the Chinese Academy of Medical Sciences, Tianjin

All Listed Sponsors
lead

Beijing Yongtai Ruike Biotechnology Company Ltd

INDUSTRY